Often, investors and Wall Street analysts focus on the short term and don't give enough thought to the long term.

These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now.

The smart money on Pfizer (NYSE: PFE) is sending a quieter signal than the financial press typically rewards: institutional ...

The payout ratio is over 100% for this high-yield healthcare giant, but don't run for the hills just yet.

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by ...

Pfizer Inc. (NYSE:PFE) is one of the best medical stocks to invest in according to billionaires. Pfizer Inc. (NYSE:PFE) ...

In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard ...

China's Innovent Biologics and U.S. pharma giant Pfizer have agreed to a global licensing and collaboration deal worth up to ...

Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. After winning a broader FDA label in metastatic castration-resistant prostate cancer (mCRPC) ...

In my March article, "Why Pfizer Remains A Strong Buy In 2026", I mainly discussed Pfizer's Q4 earnings ( PFE) and the ...

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.